Vergleich

Vorinostat (SAHA) Europäischer Partner

187,00 €
Zzgl. MwSt.
ArtNr S1047-10mM
Hersteller Selleckchem
CAS-Nr. 149647-78-9
Menge 10 mM/1 ml
Kategorie
Typ Inhibitors
Specific against other
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias MK0683, Suberoylanilide hydroxamic acid, Zolinza, HDAC;HDAC
Similar products Vorinostat
Lieferbar
Administration
Injection i.p.
Animal Models
Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells
Cell lines
LNCaP, PC-3, and TSU-Pr1
Clinical Trials
A Phase I/II study of Vorinostat on HIV RNA expression in the resting CD4+ T cells of HIV-infected patients receiving stable antiretroviral therapy is currently ongoing.
Concentrations
Dissolved in DMSO, final concentrations ca.7.5 uM
Description
Vorinostat (suberoylanilide hydroxamic acid, SAHA, Zolinza) is an HDAC inhibitor with IC50 of ca.10 nM.
Dosages
ca.100 mg/kg/day
Formulation
Dissolved in DMSO
IC50
ca.10 nM [1], ca.10 nM [1], ca.10 nM [1], ca.10 nM [1], ca.10 nM [1], ca.10 nM [1]
In vitro
Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. [1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 uM), and induces dose-dependent cell death in LNCaP cells. [2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 uM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. [3] Vorinostat treatment at 1 uM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. [4]
In vivo
Administration of Vorinostat (ca.100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. [2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. [5]
Incubation Time
1, 2, 3 and 4 days
Kinase Assay
Immunoprecipitation-HDAC assays, The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12, 000 g for 10 minutes at 4 C. Supernatants are precleared with 30 uL of 50% protein G-Sepharose slurry for 1 hour at 4 C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 C with 10 ug of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 uL of 50% protein G-Sepharose slurry is added for 1 hour at 4 C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 uL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an 3H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [3H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 C.
Method
Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion.
Molecular Weight (MW)
264, 3
Picture ChemicalStructure Description
Vorinostat (SAHA) Chemical Structure
Picture Description 1
Data from [Nat Biotechnol , 2011, 29, 255-265], Vorinostat (SAHA)purchased from Selleck, Differential effects of HDAC inhibitors on histone and tubulin acetylation. Immunofluorescence analysis of histone H3 (K9ac/K14ac) and tubulin acetylation in HeLa cells treated for 4 h with vehicle, SAHA (10 M), tacedinaline (50 M), PCI-24781 (20 M. (a) Mapping of histone acetylation in K562 cells treated with HDAC inhibitors by LC-MS/MS. Cells were treated with TSA (10 M), SAHA (5 M), PCI-24781 (2 M), tacedinaline (50 M) for 6 h. Histones were extracted from cells and acetylated peptides were quantified after isobaric tagging.
Picture Description 2
Data from [Invest New Drugs , 2010, 30(2), 541-547], Vorinostat (SAHA)purchased from Selleck, Treatment with SAHA sensitizes breast cancer cells to TRAILinduced apoptosis. BT-474 and MDA-MB-231 cells were incubated for 8 h with SAHA at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some of the cultures for an additional 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content as described in the Materials and methods. The results show the mean and S.E.M. of three independent experiments
Solubility (25C)
DMSO 53 mg/mL, Water <1 mg/mL, Ethanol 3 mg/mL
Storage
2 years -20CPowder, 2 weeks4Cin DMSO, 2 months-80Cin DMSO

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 10 mM/1 ml
Lieferbar: In stock
Listenpreis: 187,00 €
Preis: 187,00 €
lieferbar

Lieferung vsl. bis 14.08.2025 

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen